20/20 Biolabs

Founder‑CEO Jonathan Cohen brings IP, diagnostics, and business development experience; the CFO has public company reporting and financing background; the board includes experienced lab and oncology leaders.

Execution in 1H 2026 showed mix improvement and accounts added, but investor‑facing structures (Streeterville, warrant repricings) and Nasdaq deficiency notices detract from shareholder alignment. Track record on scaling predictable revenue and achieving payer adoption is still nascent.